S
epsis is the leading cause of intensive care unit admissions, with high mortality and morbidity. In septic patients, widespread vascular leakage and inflammation secondary to endothelial activation and dysfunction is the primary mechanism of multiorgan failure. 1 Endothelial cells are the key sentinel cells detecting microbial infection through the activation of pattern recognition receptors to mount an inflammatory response. Endothelial activation during sepsis leads to the production of multiple proinflammatory cytokines and upregulation of adhesion molecules E/P-selectins and ICAM (intercellular adhesion molecule)-1 essential for polymorphonuclear neutrophil (PMN) rolling, adhesion, and transendothelial PMN migration. 2 Sustained activation of endothelium results in massive infiltration of PMNs, hyperinflammation, tissue damage, and ultimately organ dysfunction. 3 Therefore, maintenance or reconstitution of vascular endothelial homeostasis after a major systemic injury is a crucial determinant of outcome in sepsis. 1, 4 However, the underlying mechanisms limiting the severity of endothelial activation during sepsis remain to be identified.
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Activation of NF-κB (nuclear factor-κB) is critical for regulating the expression of inflammatory genes and adhesion molecules. 5 The NF-κB activation cascade is initiated by endotoxin lipopolysaccharide binding to TLR (Toll-like receptor)-4, which activates adaptor protein MyD88 (myeloid differentiation factor)-dependent and MyD88-independent signaling pathways. 6, 7 MyD88 associates with IRAK (IL [interleukin]-1 receptor-associated kinase), which recruits E3 ligase TRAF6 (tumor necrosis factor [TNF] receptor-associated factor 6), 6, [8] [9] [10] which in turn interacts with the TAK1 (transforming growth factor-β-activated kinase 1) complex. TAK1 activates IKK (IκB [inhibitor protein κB] kinase), leading to the phosphorylation and degradation of IκB, and consequent release of NF-κB and its nuclear translocation. 11, 12 TRAF6 lies downstream of TNF receptor, IL-1 family and most TLR (TLR1-9) and functions as a node controlling the activation of NF-κB. The ubiquitination of TRAF6 is a key regulatory event controlling the level of TRAF6 expression and TAK1 activation. 13, 14 TRAF6 can be ubiquitinated through the E3 ubiquitin ligase in its RING (really interesting new gene) domain.
14 K48-linked ubiquitination of TRAF6 leads to its degradation via the 26S proteasome, whereas K63-linked polyubiquitination is essential for activation of TAK1 kinase and subsequent NF-κB signaling. 13, 14 The Hippo signaling pathway consists of a serine kinase cascade with associated regulatory and scaffolding proteins that transcriptionally regulate the expression of genes controlling growth. The Ser/Thr kinase Hippo in Drosophila (Mst1 [mammalian sterile 20-like kinase] and Mst2 in mammals) and Sav1 (salvador) form a complex that phosphorylates and activates LATS1/2 (large tumor suppressor) kinases, which in turn phosphorylate YAP (Yes-associated protein) and TAZ (transcriptional coactivator with PDZ-binding motif), the 2 downstream effectors of the Hippo pathway, causing them to be retained in the cytoplasm. [15] [16] [17] Dephosphorylation of YAP and TAZ induces their nuclear translocation and activates expression of genes that promote cell proliferation and inhibit apoptosis. 18, 19 YAP is a potent oncogene first identified by its ability to associate with Yes and Src tyrosine kinases. 20 As a transcriptional coactivator, YAP activates the expression of target genes important for cell survival, chemotaxis, differentiation, and proliferation. 21, 22 Activation of YAP or loss of its upstream negative regulators leads to striking overgrowth and tumor phenotypes. 23 Although Hippo/YAP signaling is important in oncogenesis, little is known about how YAP signals inflammation. We previously showed that Gram-positive bacteria activated Hippo signaling through Toll-dependent pathway in Drosophila. 24 It is unknown if Hippo/YAP signaling also regulates inflammatory response induced by sepsis.
We identified here a previously unrecognized YAPdependent pathway regulating NF-κB activation in endothelial cells via a direct interaction of YAP with TRAF6. YAP induced the degradation of TRAF6 via K48 ubiquitination while simultaneously suppressing K63-linked autoubiquitination to prevent downstream formation and activation of the TAK1 complex and NF-κB signaling. We found that deletion of YAP expression in endothelial cells triggered inflammation even in the absence of infection and caused hyperinflammation in response to lipopolysaccharide or cecal ligation and puncture (CLP) challenge through unfettered activation of NF-κB signaling. These results establish an important functional linkage between endothelial YAP and inhibition of 
Novelty and Significance
What Is Known?
• Microvascular endothelial activation and dysfunction are critical determinants in the progression from sepsis to organ failure.
• YAP (Yes-associated protein) transcriptionally promotes cell survival, chemotaxis, differentiation, and proliferation.
What New Information Does This Article Contribute?
• Endothelial-specific deletion of YAP exaggerates sepsis-induced vascular inflammation, lung inflammatory injury, and cardiovascular dysfunction.
• YAP limits NF-κB (nuclear factor-κB) activation via modification of the signaling adaptor TRAF6 (tumor necrosis factor receptor-associated factor 6).
Systemic endothelial activation and dysfunction induce vascular inflammation and disruption of microvascular barrier integrity leading to microvascular leak, tissue edema, shock, organ failure, and ultimate death. However, the molecular mechanisms responsible for controlling endothelial activation remains unknown. Herein, we identified a crucial role of cytoplasmic YAP as a checkpoint modulator of endothelial activation and vascular inflammation. YAP suppressed inflammatory signaling by interacting with TRAF6 and prevented the activation of NF-κB by enhancing degradation of TRAF6 via K48 ubiquitination as well as suppressing K63-linked ubiquitination. Our results suggest that endothelial YAP may be a novel therapeutic target for prevention and treatment of sepsis-induced tissue inflammatory injury and organ failure.
NF-κB signaling through direct interaction of cytoplasmic YAP with TRAF6 and point to a fundamental role of YAP in limiting activation of endothelial cells.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. Details of materials and experimental procedures are available in the Online Data Supplement.
Mice
Endothelial-specific YAP-deficient mice were generated by crossing YAP-floxed mice (YAP f/f ) with Tie2-Cre transgenic mice. All mice used in the experiments were the littermates of genotypes of YAP f/f with Cre gene as endothelial YAP-conditional knockout (CKO) mice (these mice are hereafter referred to as YAP-CKO). Mice only carry YAP f/f as wild-type (WT) mice.
Mouse Models of Endotoxemia and Polymicrobial Sepsis
All experimental mice were sex-and age-matched. Endotoxemia was induced with injection of lipopolysaccharide (5 mg/kg, IP). Polymicrobial sepsis was created by CLP.
Intravital Microscopy
The cremaster muscle was exposed. PMNs and monocytes were visualized by infusion of Alexa Fluor 647-conjugated anti-Ly-6G and Alexa Fluor 647-conjugated anti-F4/80 antibody, respectively. The rolling influx and number of adherent PMNs or monocytes were determined.
Generation of Bone Marrow Chimeras
The irradiated mice (CD45.2) were transplanted with bone marrow cells isolated from Ly5.1 (CD45.1). Six weeks after transplantation, all the recipients were used for measurement of lung inflammation.
Depletion of TRAF6 in Mouse Pulmonary Endothelium
TRAF6 was depleted in mouse pulmonary vasculature by intravenous injection of cationic liposome-TRAF6 small interfering RNA (siRNA) complexes.
Statistics
One-way ANOVA and Student Newman-Keuls test for post hoc comparisons were used to test differences between the means of 3 or more groups. Mann-Whitney U test was performed to detect significant differences between 2 experimental groups. Difference in the survival between 2 groups was determined by Mantel-Cox test. All data are expressed as mean±SD. Differences were considered significant when P<0.05.
Results

Endothelial Cell-Specific Deletion of YAP Basally Activates Inflammation
To study the functional significance of YAP expression in endothelial cells, we generated YAP-CKO mice (Tie2-Cre; YAP f/f ; Online Figure IA ). Cre and YAP-flox alleles in mice were identified by PCR (Online Figure IB) . Specificity and efficiency of YAP deletion were determined by real-time quantitative reverse transcription PCR and Western blotting. We found >85% reduction in YAP mRNA (Online Figure IC) and protein levels in isolated mouse lung endothelial cells but not in nonendothelial cells (epithelial cells and fibroblasts; Online Figure ID ). Immunoblotting assessment of YAP protein expression also exhibited 60% reduction in whole lung tissues (Online Figure IE) . 
Enhanced Inflammatory Response to Endotoxin and Polymicrobial Sepsis in YAP-CKO Mice
We next examined whether baseline increases in endothelial activation enhanced the susceptibility of YAP-CKO mice to endotoxemia. In YAP-CKO mice challenged with lipopolysaccharide, the numbers of total cells (Online Figure IIIA Figure IVE) released by activated endothelium were also elevated both basally and after lipopolysaccharide challenge. Lung tissue from WT counterparts after lipopolysaccharide challenge had severe histological changes, including alveolar congestion, exudates, and infiltration of inflammatory cells, whereas these alterations were markedly exacerbated in lipopolysaccharide-challenged YAP-CKO mice, as evident by the significantly higher lung injury score ( Figure 1B ). To assess whether endothelial YAP knockout also augmented the increase in lipopolysaccharide-induced pulmonary vascular permeability, we measured lung albumin-bound Evans blue dye extravasation, an indicator of vascular leakage. We observed a striking aggravation of lipopolysaccharide-induced pulmonary vascular hyperpermeability in YAP-CKO mice ( Figure 1C ). Production of the proinflammatory cytokines IL-6, TNF-α, and IL-1β was greatly elevated in YAP-CKO mice after lipopolysaccharide challenge as compared with WT littermates ( Figure 1D ). Importantly, YAP-CKO mice had a significantly higher mortality rate after challenge with lethal dose of lipopolysaccharide than WT counterparts ( Figure 1E ). In a polymicrobial sepsis model, deletion of YAP also enhanced CLP-induced increase in serum sICAM-1 (Online Figure  IVF) , sVCAM-1 (Online Figure IVG) , IL-6 ( Figure 1F ), and TNF-α ( Figure 1G ). In addition, mean blood pressure ( Figure 1H ), ejection fraction ( Figure 1I and 1J), and fractional shortening ( Figure 1I and 1K) dramatically decreased in YAP-CKO mice after CLP challenge compared with WT mice. Depletion of endothelial YAP resulted in 0% survival after CLP, whereas WT mice exhibited ≈70% survival within 96 hours ( Figure 1L ).
Because Cre recombinase driven by the Tie2 promoter was used to delete yap in the mouse studies, this promoter may also induce YAP deletion in hematopoietic cells. 25 To determine any contribution of YAP deletion in myeloid cells to the enhanced endothelial immune response, we generated chimeric mice ( Because Cre is known to have nonspecific effects in multiple cell and tissues that could influence inflammation, we performed an additional experiment in Tie2-Cre mice to address the potential role of Cre in a focused comparative in vivo study with YAP f/f and YAP-CKO mice. Tie2 Cre mice 
YAP Suppresses PMN and Monocyte Recruitment in Microvessels
To investigate the role of YAP in systemic vascular inflammation, we performed real-time fluorescence intravital microscopy in a mouse model of lipopolysaccharide-induced cremaster venular inflammation. 26 YAP-CKO mice exhibited markedly increased number of adherent PMNs compared with WT mice both basally and after lipopolysaccharide challenge ( Figure 3A and 3B) . PMN rolling was reduced in YAP-CKO mice compared with that in WT mice both basally and after lipopolysaccharide challenge ( Figure 3C ; Online Movie I through IV). As measured by anti-F4/80 antibodies, monocyte adhesion to the inflamed endothelium was also enhanced in lipopolysaccharide-challenged YAP-CKO mice, compared with WT mice (Online Figure VII) . Because of the small % in leukocytes, no rolling and adherent monocytes were detected in unchallenged WT and CKO mice (data not shown).
We also performed immunohistochemistry in cremaster muscle vessels taken from the mice after intravital microscopy to determine E-selectin and ICAM-1 expression, which mediates PMN rolling and adhesion, respectively. 2, 27 Expressions of E-selectin and ICAM-1 in endothelial cells of YAP-CKO mice were significantly increased under basal conditions compared with control mice, and expressions of both adhesion proteins were further increased after lipopolysaccharide challenge ( Figure 3D through 3F ).
YAP Negatively Regulates Endothelial Activation
To further determine the role of YAP in the endothelial activation during sepsis, we first examined the expression of YAP in response to lipopolysaccharide in HUVECs (human umbilical vein endothelial cells). We observed that YAP protein expression increased after lipopolysaccharide stimulation in a time-dependent manner, peaked at 4 hours, and then gradually decreased to basal level at 24 hours ( Figure 4A) . A similar result of YAP mRNA expression was seen in HUVECs after lipopolysaccharide stimulation by real-time quantitative reverse transcription PCR ( Figure 4B ). Expression of YAP protein was also elevated at 4 hours after stimulation with other stimuli TNF-α or H 2 O 2 in HUVECs ( Figure 4C , left) and human lung microvascular endothelial cells (HLMVECs; Figure 4C , right). To verify whether lipopolysaccharide regulates YAP protein expression in vivo, we challenged mice by IP administration with lipopolysaccharide to induce acute lung injury. As shown in Figure 4D , YAP protein expression in both endothelial and nonendothelial cells was increased in vivo after lipopolysaccharide challenge. We next deleted YAP protein in HUVECs with CRISPR/ Cas9 or overexpressed it with recombinant Flag-YAP cDNA and measured the production of proinflammatory cytokines on challenging the cells with lipopolysaccharide. YAP deletion ( Figure 5A ) significantly increased the production of IL-6 and IL-1β over time ( Figure 5B ). Conversely, overexpression of YAP ( Figure 5C ) markedly attenuated the production of IL-6 and IL-1β ( Figure 5D ). Leukocyte adhesion via endothelial ICAM-1 and E-selectin and subsequent transendothelial migration are hallmarks of endothelial activation and inflammation and are central features of the innate immune function of endothelial cells. 28 We found that depletion of YAP in HUVECs ( Figure 5E 
YAP Interaction With TRAF6 Inhibits NF-κB Activation
We next addressed the mechanism by which YAP modulated lipopolysaccharide-induced endothelial activation. In endothelial cells, exposure to lipopolysaccharide induces endothelial activation through TLR4 and triggers proinflammatory cytokine secretion and expression of adhesion molecules via NF-κB signaling. 28 Here, we first assessed whether YAP interacted with components of the TLR4 signaling pathway. We observed no association of YAP with many key components of the pathway TLR4, MyD88, IRAK-1, and IκBα (Online Figure IXA through IXD) To analyze the possibility of direct interaction of YAP and TRAF6, we searched TRAF-binding domains in YAP and identified that human YAP has a major TRAF-binding directly associated with Myc-his-TRAF6 ( Figure 6D ; Online Figure XB) .
To determine whether YAP regulated NF-κB activation through its binding to TRAF6, we next expressed NF-κB luciferase reporter together with TRAF6 and increasing concentrations of YAP-WT or YAP-mutant cDNA in HEK293T cells. YAP-WT strongly inhibited NF-κB activation in a concentration-dependent manner ( Figure 6E ), whereas YAP-mutant failed ( Figure 6F ). To further elucidate the effects of YAP on NF-κB signaling in endothelial cells in vivo, we isolated lung endothelial cells from WT and YAP-CKO mice challenged with lipopolysaccharide and observed that YAP deletion significantly increased NF-κB p65 phosphorylation (activation), IκBα degradation, and accumulation of p65 and p50 in nucleus both basally and after lipopolysaccharide challenge compared with control WT cells ( Figure 6G ; Online Figure  XC through XE).
YAP Modulates Ubiquitination and Degradation of TRAF6 in Endothelial Cells
We next determined the mechanism of YAP-mediated TRAF6 suppression of NF-κB activation in endothelial cells. We observed that CRISPR/Cas9 knockout of YAP in endothelial cells basally upregulated TRAF6 protein expression and also enhanced lipopolysaccharide-induced TRAF6 protein expression as compared with control endothelial cells stimulated with lipopolysaccharide ( Figure 7A ; Online Figure XIA) . We also observed in HEK293T cells transiently transfected with Myc-his-TRAF6 and Flag-YAP that YAP inhibited TRAF6 protein expression in a concentration-dependent manner ( Figure 7B ; Online Figure XIB ). Based on these findings, we addressed the possibility that YAP functions by promoting TRAF6 degradation through ubiquitination. Proteins are targeted for degradation by the proteasome with covalent attachment of K48-linked polyubiquitin chains, whereas K63-linked ubiquitin activates the downstream TAK1 activation important for NF-κB activation. 13, 30 We found that deletion of YAP in HUVECs significantly decreased total and K48-linked ubiquitination of TRAF6 but increased K63-linked ubiquitination of TRAF6 ( Figure 7C ; Online Figure XIC) . To validate the role of YAP in the mechanism of ubiquitination of TRAF6, we transfected HEK293T cells with Flag-YAP, Myc-his-TRAF6, and HA (hemagglutinin)-tagged ubiquitin (HA-Ub) and performed the in vivo ubiquitination assay. Expression of Flag-YAP increased total Myc-his-TRAF6 ubiquitination ( Figure 7D ; Online Figure XID) . To identify the type of TRAF6 ubiquitination regulated by YAP, we transfected HEK293T cells with Flag-YAP and Myc-his-TRAF6 together with plasmids encoding K48-linked (HA-K48) ( Figure 7E ; Online Figure XIE 
TRAF6 Depletion in Endothelial Cells Rescues Augmented Inflammatory Phenotype of YAP-CKO Mice
To address whether TRAF6 expression was required and sufficient for lipopolysaccharide-induced increase in lung inflammation in YAP-CKO mice, we depleted TRAF6 in YAP-CKO lung vascular endothelium using liposomes incorporating TRAF6 siRNA. Injection of liposomes containing scrambled siRNA was used as control. Western blot analysis of pulmonary endothelial cells isolated from YAP-CKO mice transfected with siRNAs confirmed efficiency of TRAF6 depletion ( Figure 8A ; Online Figure XIIA 
Discussion
YAP, a transcriptional coactivator, serves as a key regulator of tissue growth and organ size by promoting cell proliferation and suppressing apoptosis. 31 In cardiac and vascular smooth muscle cells, YAP is an important regulator of cardiovascular development. 32 Here, we identified a crucial role of cytoplasmic YAP as a checkpoint modulator of endothelial activation and vascular inflammation. Specific deletion of YAP in endothelial cells did not alter the size of organs; instead, it induced vascular inflammation in the absence of inflammatory stimuli and greatly augmented inflammation during endotoxemia and polymicrobial sepsis. YAP negatively regulated inflammatory signaling by directly interacting with the E3 ligase TRAF6 which induced degradation of TRAF6 through K48-linked TRAF6 ubiquitination and simultaneously inhibited K63-linked autoubiquitination of TRAF6.
Our study clearly demonstrated the requisite role of YAP in limiting endothelial activation, and thereby excessive vascular inflammation, and organ dysfunction. This notion was strongly supported by studies in 2 murine experimental models of sepsis in which YAP was conditionally deleted in endothelial cells (YAP-CKO mice). Although mice with endothelial cell-specific deficiency of YAP did not display any gross phenotypic alteration up to adulthood, PMN infiltration into the lung and enhanced expression of adhesion molecules suggest a mild lung endothelial inflammatory activation in YAP-CKO mice. The inflammatory response to lipopolysaccharide and polymicrobial sepsis in YAP-CKO mice was markedly enhanced as evident by higher tissue PMN infiltration, severe lung histopathologic changes, and edema formation. Intravital microscopy studies in the cremaster muscle microcirculation also showed marked PMN adhesion to cremasteric vessel endothelial cells of YAP-CKO mice both in the absence of inflammatory stimulus and after lipopolysaccharide exposure. Because Tie2 promoter/enhancer-driven Cre expression was used to deplete the yap gene in endothelial cells in our study, a possible concern is that augmented endothelial activation and vascular inflammation may also result from deletion of the yap gene in hematopoietic cells. To circumvent this concern, we transplanted either WT or YAP-CKO bone marrow cells into lethally irradiated YAP-CKO or WT mice and observed similar levels of endothelial activation and inflammatory responses in these mice. Thus, deletion of YAP in endothelial cells, as opposed to hematopoietic cells, was responsible for endothelial cell activation and inflammation seen in the YAP-CKO mice.
TLR4/NF-κB signaling is essential for endothelial activation and the consequent inflammation during sepsis. 5, 28 Our findings indicated that YAP prevented NF-κB activation by direct interaction with TRAF6 in endothelial cells. We observed that coexpression of YAP-WT cDNA and TRAF6 cDNA inhibited NF-κB activation. Furthermore, amino acid substitution mutations within the TRAF-binding site (Ser-LeuGln-Glu) of YAP abolished the interaction of YAP and TRAF6. Interestingly, coexpression of YAP-mutant and TRAF6 cDNA failed to affect NF-κB activation. Thus, it seems that specific binding of YAP to TRAF6 leading to inhibiting NF-κB activation plays a crucial role in the immunomodulatory function of YAP in endothelial cells. TRAF6 on the basis of its ligase function is a key downstream regulator of multiple immunoregulatory receptors, including members of the TNF receptor superfamily, TLR family, transforming growth factor-β receptors, and T cell receptor.
33 CD40-TRAF6 interactions are known to play an essential role in the development of atherosclerosis and restenosis. 34, 35 The ubiquitination of TRAF6 is a crucial mechanism for NF-κB activation.
36,37 TRAF6 can be ubiquitinated with both K48-linked degradative and K63-linked nondegradative chains at multiple locations. In the latter case, the N-terminal RING domain of TRAF6 functions as an E3 ubiquitin ligase that facilitates its own site-specific ubiquitination through the generation of K63-linked ubiquitin chains.
36 K63-linked autoubiquitination of TRAF6 is essential for the formation and activation of TAK1 complex and NF-κB signaling. 38 In this study, deletion of YAP in endothelial cells upregulated TRAF6 expression, prevented K48 ubiquitination of TRAF6, and significantly enhanced K63 ubiquitination of TRAF6. These results suggest that YAP prevented the activation of NF-κB by both enhancing the degradation of TRAF6 via K48 ubiquitination and blocking TAK1 activation via suppression of K63-linked ubiquitination. Taken together, YAP expression controls endothelial activation and thereby prevents hyperinflammatory response to endotoxin through restraining TRAF6-mediated NF-κB activation.
In the present study, YAP expression in human and mouse endothelial cells was upregulated by lipopolysaccharide, but then the expression recovered toward baseline after the inflammatory response exaggerated. In tumor-initiating stemlike cells 39 and adipose tissue-derived mesenchymal stem cells, 40 TLR ligands also induced the expression of YAP1 and TAZ. These findings suggest a negative feedback loop between YAP and TLRs, whereby TLR signaling results in increased expression of YAP, which limits activation of NF-κB to proceed and holds the inflammatory response in check. Thus, YAP signaling may act as a molecular brake to restrict endothelial activation and prevent excessive inflammation and organ failure.
YAP is known to play a key role in cell proliferation, survival, differentiation, tissue regeneration, and organ size determination. 41 Global YAP knockout mice died at embryonic day 8.5. 42 Kidney-specific CKO of YAP in mice resulted in defective kidneys with abnormal glomeruli, ducts without lumen. 43 Ectopic expression of YAP in the liver induced liver enlargement and the liver reverted to a normal size on switching-off YAP overexpression. 44, 45 Liver enlargement was also observed with knockout of Mst1/2 (molecules upstream of YAP). However, there was no discernable change in the size of the kidney, intestines, and lung in Mst1/2 knockout mice. 46 We observed that the size and weight of vital organs in endothelial YAP knockout mice were normal, indicating that YAP expression in endothelial cells is dispensable for organ growth and development. The primary role of YAP in endothelial cells seems to modulate their activation secondary to YAP interaction with TRAF6, and thereby restrict the activation of NF-κB.
In contrast to our observation that YAP deletion in endothelial cells enhanced vascular inflammation, a study showed that YAP/TAZ knockdown prevented oscillatory shear stressinduced proinflammatory responses, as evidenced by reduced expression of endothelial adhesion molecules and THP1 (Tamm-Horsfall protein 1) monocyte attachment. 47 YAP/TAZ activation in HUVECs transfected with constitutively active YAP (S127A) and TAZ (S89A; CA-YAP/TAZ) also increased monocyte-endothelial adhesion and the release of proinflammatory cytokines IL-6 and IL-8. 48 The reasons for the discrepancy with our findings are not clear. It is possible that the differences are because of the cell types used and the inflammatory stimuli. Here, we determined the role of YAP in modulating lipopolysaccharide-induced activation of NF-κB in which YAP functioned by interacting with TRAF6 to suppress NF-κB signaling.
In summary, to our knowledge, this study was the first to provide both in vitro and in vivo evidence that YAP is an essential regulator of endothelial activation and inflammation. YAP functions by interacting with TRAF6 and prevents the activation of NF-κB by enhancing degradation of TRAF6 via K48 ubiquitination as well as suppressing K63-linked ubiquitination. The increase in endothelial YAP expression induced by endotoxemia serves as an important checkpoint limiting the severity of endothelial activation and inflammation ( Figure 8E ). In this context, upregulation and stabilization of YAP expression in endothelial cells may be a novel pharmacological approach for preventing sepsis-induced tissue inflammatory injury and organ failure.
